New drug combo shows promise for Hard-to-Treat lymphomas

NCT ID NCT03598608

Terminated Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in some participants. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 B-cell neoplasm classic Hodgkin lymphoma diffuse large B-cell lymphoma Hodgkins lymphoma indolent B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN DISEASE LYMPHOMA, B-CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351)

Bologna, Emilia-Romagna, 40138, Italy
BC Cancer ( Site 0107)

Vancouver, British Columbia, V5Z 1L3, Canada
Banner MD Anderson Cancer Center ( Site 0020)

Gilbert, Arizona, 85234, United States
CancerCare Manitoba ( Site 0101)

Winnipeg, Manitoba, R3E 0V9, Canada
Chaim Sheba Medical Center. ( Site 0380)

Ramat Gan, 5262001, Israel
City of Hope ( Site 0001)

Duarte, California, 91010, United States
Concord Repatriation & General Hospital ( Site 0203)

Concord, New South Wales, 2139, Australia
Dana Farber Cancer Institute ( Site 0002)

Boston, Massachusetts, 02215, United States
Fox Chase Cancer Center ( Site 0019)

Philadelphia, Pennsylvania, 19111, United States
Hadassah Ein Karem Jerusalem ( Site 0383)

Jerusalem, 9112001, Israel
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352)

Rozzano, Milano, 20089, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354)

Meldola, Forli-Cesena, 47014, Italy
Jewish General Hospital ( Site 0105)

Montreal, Quebec, H3T 1E2, Canada
Monash Health ( Site 0201)

Clayton, Victoria, 3168, Australia
Pacific Cancer Care ( Site 0006)

Monterey, California, 93940, United States
Princess Alexandra Hospital ( Site 0204)

Woollongabba, Queensland, 4102, Australia
Princess Margaret Cancer Centre ( Site 0100)

Toronto, Ontario, M5G 2M9, Canada
Rambam Medical Center ( Site 0382)

Haifa, 3109601, Israel
Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)

Los Angeles, California, 90095, United States
Sourasky Medical Center ( Site 0381)

Tel Aviv, 6423906, Israel
St Vincent s Hospital (Melbourne) Limited ( Site 0202)

Fitzroy, Victoria, 3065, Australia
Texas Oncology-Austin Midtown ( Site 8002)

Austin, Texas, 78705, United States
U. klinikum Koeln AOER ( Site 0326)

Cologne, North Rhine-Westphalia, 50937, Germany
Universitaetsklinikum Leipzig AOeR ( Site 0327)

Leipzig, Saxony, 4103, Germany
University of California San Francisco ( Site 0023)

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.